TFRC and breast cancer: In breast cancer, targeting the epithelial-mesenchymal transition (EMT)-MET process and cancer stem cells can trigger ferroptosis in cancer cells, thus inhibiting tumor growth and preventing invasion and metastasis [173–176], and lapatinib causes ferroptosis in breast cancer cells through iron accumulation by increasing the expression of TF and TFR and decreasing the expression of FPN [177].